| Marc S Frost, MD | |
|
3980 Sheridan Dr, Suite 200, Amherst, NY 14226-1727 | |
| (716) 250-2000 | |
| Not Available |
| Full Name | Marc S Frost |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 34 Years |
| Location | 3980 Sheridan Dr, Amherst, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841256336 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 186981 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brooks-tlc Hospital System, Inc | Dunkirk, NY | Hospital |
| Sisters Of Charity Hospital | Buffalo, NY | Hospital |
| Bertrand Chaffee Hospital | Springville, NY | Hospital |
| Mercy Hospital Of Buffalo | Buffalo, NY | Hospital |
| Kaleida Health | Buffalo, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dent Neurologic Group Llp | 1951298033 | 102 |
News Archive
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a strategy that doubled screening rates for colorectal cancer, the second leading cause of cancer death in the United States, among patient groups who historically have had lower rates.
Researchers have found that more intensive chemotherapy maintenance for ovarian cancer could be beneficial for patients. The results of the study were presented at the ESMO Congress 2019 in Barcelona, Spain last weekend on the 28th of September.
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
For some, COVID-19 can result in severe pneumonia or even death, while others remain purely asymptomatic. A diagnostic tool could help physicians predict if a patient with COVID-19 will worsen.
In the August 12 issue of the journal Nature, researchers at the University of Pennsylvania detail the creation of a library of small protein-like molecules that can self-assemble to form hollow corkscrew-like pores that could mimic pores seen in living systems.
› Verified 5 days ago
| Entity Name | Dent Neurologic Group Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497850911 PECOS PAC ID: 1951298033 Enrollment ID: O20040303000238 |
News Archive
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a strategy that doubled screening rates for colorectal cancer, the second leading cause of cancer death in the United States, among patient groups who historically have had lower rates.
Researchers have found that more intensive chemotherapy maintenance for ovarian cancer could be beneficial for patients. The results of the study were presented at the ESMO Congress 2019 in Barcelona, Spain last weekend on the 28th of September.
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
For some, COVID-19 can result in severe pneumonia or even death, while others remain purely asymptomatic. A diagnostic tool could help physicians predict if a patient with COVID-19 will worsen.
In the August 12 issue of the journal Nature, researchers at the University of Pennsylvania detail the creation of a library of small protein-like molecules that can self-assemble to form hollow corkscrew-like pores that could mimic pores seen in living systems.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marc S Frost, MD 3980 Sheridan Dr, Suite B, Amherst, NY 14226-1727 Ph: (716) 250-2000 | Marc S Frost, MD 3980 Sheridan Dr, Suite 200, Amherst, NY 14226-1727 Ph: (716) 250-2000 |
News Archive
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a strategy that doubled screening rates for colorectal cancer, the second leading cause of cancer death in the United States, among patient groups who historically have had lower rates.
Researchers have found that more intensive chemotherapy maintenance for ovarian cancer could be beneficial for patients. The results of the study were presented at the ESMO Congress 2019 in Barcelona, Spain last weekend on the 28th of September.
Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company's Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection.
For some, COVID-19 can result in severe pneumonia or even death, while others remain purely asymptomatic. A diagnostic tool could help physicians predict if a patient with COVID-19 will worsen.
In the August 12 issue of the journal Nature, researchers at the University of Pennsylvania detail the creation of a library of small protein-like molecules that can self-assemble to form hollow corkscrew-like pores that could mimic pores seen in living systems.
› Verified 5 days ago
Syed Jaffri, M.D.,M.R.C.,PSYCH. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2800 Sweet Home Rd, #8, Amherst, NY 14228 Phone: 716-691-0639 Fax: 716-691-0410 | |
Horacio Capote, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3980 Sheridan Dr Ste 500, Dent Neurologic Group, Llp, Amherst, NY 14226 Phone: 716-250-2000 Fax: 716-636-1365 | |
Ms. Jesslyn Lee Weber, PA-C Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3980 Sheridan Dr, Amherst, NY 14226 Phone: 716-250-2000 | |
Maria T Cartagena, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 85 Bryant Woods S, Amherst, NY 14228 Phone: 716-689-3333 Fax: 716-689-9866 | |
Maria K Nickolova, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 85 Bryant Woods S, Amherst, NY 14228 Phone: 716-689-3333 Fax: 716-689-9866 | |
Dr. Cynthia Beatty, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 300 Essjay Rd, Amherst, NY 14221 Phone: 716-932-6080 | |
Dr. Howard C Wilinsky, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 4955 N Bailey Ave, Ste 130, Amherst, NY 14226 Phone: 716-835-1246 Fax: 716-835-0396 |